The abstract is read at the publisher; the summary is JClub's.
In UK Biobank participants, clonal hematopoiesis of indeterminate potential (CHIP) is linked to markedly higher myeloid malignancy risk (HR = 9.56), especially when biologically older.
- Why it matters: CHIP and biological aging each relate to cancer risk, but their combined effect is unclear, limiting how well clinicians can stratify risk for specific cancers.
- What they did: Using 332 911 UK Biobank participants, investigators defined CHIP as pathogenic variants with variant allele fractions ≥2% and measured biological aging via PhenoAgeAccel, then fit Cox models for 25 cancers and tested CHIP–aging interactions.
- The result: Biologically older participants had higher risks of hematologic neoplasms (HR = 1.42), and CHIP carriers who were biologically older had higher risks of hematologic neoplasms (HR = 6.56); additive interaction accounted for 40% of excess risk for hematologic neoplasms and 27% for lung cancer, with multiplicative interaction for hematologic neoplasms (Pinteraction < .001).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.